The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis

Overview

Journal Front Public Health

Specialty Public Health

Date 2022 Aug 1

PMID 35910897

Authors

Yuntao Zou

Doudou Huang

Qian Jiang

Yanglin Guo

Chider Chen

Affiliations

Soon will be listed here.

Abstract

Background: COVID-19 is a respiratory illness caused by SARS-CoV-2. The most recent variant is Omicron (line B.1.1.529), which was first identified in South Africa in November 2021. The concern with this variant is the ineffectiveness of vaccines currently available. We aim to systematically evaluate the effectiveness of the currently available COVID-19 vaccines and boosters for the Omicron variant.

Methods: We searched the PubMed, Embase, the Cochrane Library and Web of Science databases from inception to June 5th, 2022. Studies that examined the effectiveness of SARS-CoV-2 vaccines against the Omicron variant infection were included. Random-effects model was used to estimate the pooled vaccine effectiveness against the Omicron variant.

Results: A total of 13 studies were included to evaluate the effectiveness of the vaccine against the Omicron variant, and 11 studies were included to compare the effectiveness between the two-dose and three-dose (booster) vaccinations. Full vaccination (two-dose with or without booster) showed a protective effect against the Omicron variant compared to no vaccination (OR = 0.62, 95% CI: 0.56-0.69), while the effectiveness decreased significantly over 6 months after the last dose. The two-dose vaccination plus booster provided better protection against the Omicron variant compared to the two-dose vaccination without booster (OR = 0.60, 95% CI: 0.52-0.68). Additional analysis was performed for the most commonly used vaccines in the United Staes: BNT162b2(Pfizer) (OR = 0.65, 95% CI: 0.52-0.82) and mRNA-1273(Moderna) (OR = 0.67, 95% CI: 0.58-0.88) vaccines in the US, which showed similar effectiveness compared to no vaccination.

Conclusions: The full dose of SARS-CoV-2 vaccination effectively reduces infection from the SARS-CoV-2 Omicron variant; however, the effectiveness wanes over time. The booster vaccine provides additional protection against the Omicron variant.

Citing Articles

Antibody-dependent enhancement of coronaviruses.

Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.

PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.

Key Insights into Respiratory Virus Testing: Sensitivity and Clinical Implications.

Garcia-Rodriguez J, Janvier F, Kill C Microorganisms. 2025; 13(1).

PMID: 39858831 PMC: 11767719. DOI: 10.3390/microorganisms13010063.

Dynamics of an SVEIR transmission model with protection awareness and two strains.

Chen K, Wei F, Zhang X, Jin H, Zhou R, Zuo Y Infect Dis Model. 2024; 10(1):207-228.

PMID: 39469221 PMC: 11513685. DOI: 10.1016/j.idm.2024.10.001.

Effect of vaccinations and school restrictions on the spread of COVID-19 in different age groups in Germany.

Dings C, Selzer D, Bragazzi N, Mohler E, Wenning M, Gehrke T Infect Dis Model. 2024; 9(4):1250-1264.

PMID: 39183948 PMC: 11342094. DOI: 10.1016/j.idm.2024.07.004.

Impacts of COVID-19 vaccine boosters on clinical outcomes associated with the Omicron variant in China: A cross-sectional survey.

Feng H, Chen J, Sun J, Jiang Y Vaccine X. 2024; 19:100508.

PMID: 38903607 PMC: 11187233. DOI: 10.1016/j.jvacx.2024.100508.

References

Zimmermann P, Curtis N . Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019; 32(2). PMC: 6431125. DOI: 10.1128/CMR.00084-18. View

Horne E, Hulme W, Keogh R, Palmer T, Williamson E, Parker E . Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. BMJ. 2022; 378:e071249. PMC: 10441183. DOI: 10.1136/bmj-2022-071249. View

Kirby T . New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir Med. 2021; 9(2):e20-e21. PMC: 7784534. DOI: 10.1016/S2213-2600(21)00005-9. View

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

He X, Hong W, Pan X, Lu G, Wei X . SARS-CoV-2 Omicron variant: Characteristics and prevention. MedComm (2020). 2021; 2(4):838-845. PMC: 8693031. DOI: 10.1002/mco2.110. View

Callaway E . Omicron likely to weaken COVID vaccine protection. Nature. 2021; 600(7889):367-368. DOI: 10.1038/d41586-021-03672-3. View

Tregoning J, Brown E, Cheeseman H, Flight K, Higham S, Lemm N . Vaccines for COVID-19. Clin Exp Immunol. 2020; 202(2):162-192. PMC: 7597597. DOI: 10.1111/cei.13517. View

Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C . Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022; 22(7):959-966. PMC: 9033213. DOI: 10.1016/S1473-3099(22)00141-4. View

Reardon S . How the Delta variant achieves its ultrafast spread. Nature. 2021; . DOI: 10.1038/d41586-021-01986-w. View

10.

Kirsebom F, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E . COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. Lancet Infect Dis. 2022; 22(7):931-933. PMC: 9129256. DOI: 10.1016/S1473-3099(22)00309-7. View

11.

Klein N, Stockwell M, Demarco M, Gaglani M, Kharbanda A, Irving S . Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION.... MMWR Morb Mortal Wkly Rep. 2022; 71(9):352-358. PMC: 8893336. DOI: 10.15585/mmwr.mm7109e3. View

12.

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

13.

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M . Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August.... MMWR Morb Mortal Wkly Rep. 2022; 71(4):139-145. PMC: 9351525. DOI: 10.15585/mmwr.mm7104e3. View

14.

Tseng H, Ackerson B, Luo Y, Sy L, Talarico C, Tian Y . Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022; 28(5):1063-1071. PMC: 9117141. DOI: 10.1038/s41591-022-01753-y. View

15.

Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651. PMC: 8848203. DOI: 10.1001/jama.2022.0470. View

16.

Dolgin E . Omicron is supercharging the COVID vaccine booster debate. Nature. 2021; . DOI: 10.1038/d41586-021-03592-2. View

17.

Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S . Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10.... MMWR Morb Mortal Wkly Rep. 2022; 71(7):255-263. PMC: 8853475. DOI: 10.15585/mmwr.mm7107e2. View

18.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

19.

Thakur V, Ratho R . OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol. 2021; 94(5):1821-1824. DOI: 10.1002/jmv.27541. View

20.

Collie S, Champion J, Moultrie H, Bekker L, Gray G . Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2021; 386(5):494-496. PMC: 8757569. DOI: 10.1056/NEJMc2119270. View